Jane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Jane Street Group LLC trimmed its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 56.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 84,652 shares of the company’s stock after selling 108,141 shares during the period. Jane Street Group LLC owned approximately 0.16% of Voyager Therapeutics worth $495,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $74,000. Victory Capital Management Inc. increased its position in shares of Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after acquiring an additional 1,630 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Voyager Therapeutics during the second quarter valued at approximately $128,000. Finally, Verition Fund Management LLC bought a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $216,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Trading Up 1.2 %

NASDAQ:VYGR opened at $6.04 on Monday. Voyager Therapeutics, Inc. has a 12 month low of $5.19 and a 12 month high of $11.44. The company has a market cap of $329.94 million, a PE ratio of 8.51 and a beta of 0.93. The company has a 50 day simple moving average of $6.21 and a two-hundred day simple moving average of $6.89.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the previous year, the firm posted ($0.59) EPS. Research analysts forecast that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.53% of the company’s stock.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several analyst reports. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target for the company. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Wedbush initiated coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 target price for the company. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $17.43.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.